Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

Core Insights - Galectin Therapeutics, Inc. reported significant advancements in the belapectin development program, particularly in addressing MASH cirrhosis and portal hypertension, with promising data from the NAVIGATE dataset [2][3] Financial Highlights - The company secured a $10 million line of credit, extending its cash runway through April 2027 [3] - As of December 31, 2025, Galectin had $17.7 million in unrestricted cash and cash equivalents, alongside the $10 million line of credit [10] - Research and development expenses decreased to $14.3 million in 2025 from $36.6 million in 2024, primarily due to the conclusion of the NAVIGATE trial [10] - The net loss applicable to common stockholders for 2025 was $31.0 million, or ($0.48) per share, down from a net loss of $47.2 million, or ($0.76) per share, in 2024 [10][13] Belapectin Program Highlights - Belapectin targets galectin-3, a protein involved in fibrosis and inflammation related to MASH and portal hypertension [4] - The NAVIGATE Phase 2b/3 trial showed a 43.2% reduction in varices incidence at 18 months in the intent-to-treat population and a 49.3% reduction in the per-protocol population [5] - In U.S. patients within the per-protocol population, belapectin 2 mg/kg reduced varices incidence by 68.1% compared to placebo [5] - Safety results indicated no drug-related serious adverse events, with similar rates of treatment-emergent adverse events across groups [5] Biomarker Insights - Additional analyses from the NAVIGATE trial demonstrated consistent signals across non-invasive markers of fibrosis and liver stiffness, supporting belapectin's antifibrotic activity [6][10] - The company plans to present new analyses at the EASL Congress in May 2026, including findings on reduced varices and risk reduction in portal hypertension [10]